Transport mechanism of a new behaviorally highly potent adrenocorticotropic hormone (ACTH) analog, ebiratide, through the blood- brain barrier

T Shimura, S Tabata, T Ohnishi, T Terasaki and A Tsuji

Pharma Research Laboratories, Hoechst Japan Limited, Saitama.

The binding and internalization of a novel adrenocorticotropic hormone (ACTH) analog having a potent neuromodulating effect, ebiratide (H- Met(O2)-Glu-His-Phe-D-Lys-Phe-NH(CH2)8NH2), by isolated bovine brain capillaries, were examined. Metabolism of [5-125I-His]ebiratide occurred during a 30-min incubation with bovine brain capillaries at 37 degrees C. In the presence of 20 mM EDTA, added to inhibit this metabolism, the medium, after 30 min of incubation, contained 82.3 +/- 0.5% of the unchanged ebiratide. The total binding and acid-resistant binding of [125I]ebiratide increased with time and reached an equilibrium at about 15 min. The total binding and acid-resistant binding at 30 min (as the cell/medium ratios corrected with [14C]sucrose) were 13.07 +/- 0.86 and 5.00 +/- 0.18 microliters/mg of protein, respectively. The acid-resistant binding showed significant dependence on temperature and medium osmolarity. The [125I]ebiratide binding was significantly inhibited by dansylcadaverine, an endocytosis inhibitor. The saturable acid-resistant binding was obtained by the addition of unlabeled ebiratide (100 nM-5 mM), and the maximal internalization capacity (Bmax) at 30 min was 144.2 pmol/mg of protein, with the half-saturation constant (KD) of 62.1 microM. The nonsaturable acid-resistant binding [cell/medium ratio in the presence of the unlabeled compound (1 mM or more)] was 2.2 microliters/mg of protein. The acid-resistant binding was significantly inhibited by human ACTH, poly-L-lysine, protamine and E-2078, a basic peptide, but was not inhibited by poly-L-glutamate, insulin or transferrin. These results demonstrate that ebiratide is transported through the blood-brain barrier via a basic peptide-specific absorptive-mediated endocytosis.

Volume 258, Issue 2, pp. 459-465, 08/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				S. Tanabe, Y. Shimohigashi, Y. Nakayama, T. Makino, T. Fujita, T. Nose, G. Tsujimoto, T. Yokokura, M. Naito, T. Tsuruo, et al. In Vivo and In Vitro Evidence of Blood-Brain Barrier Transport of a Novel Cationic Arginine-Vasopressin Fragment 4-9 Analog J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 561 - 568. [Abstract] [Full Text]

				Y. Sai, M. Kajita, I. Tamai, J. Wakama, T. Wakamiya, and A. Tsuji Adsorptive-mediated endocytosis of a basic peptide in enterocyte-like Caco-2 cells Am J Physiol Gastrointest Liver Physiol, September 1, 1998; 275(3): G514 - G520. [Abstract] [Full Text] [PDF]

				G. Hong, M. Bazin-Redureau, P. Gires, and J. M. Scherrmann Hepatic Disposition and Toxicity of Cationized Goat Immunoglobulin G and Fab Fragments in Isolated Perfused Rat Liver Drug Metab. Dispos., July 1, 1998; 26(7): 661 - 669. [Abstract] [Full Text]

				S. A. Thomas, T. J. Abbruscato, V. S. Hau, T. J. Gillespie, J. Zsigo, V. J. Hruby, and T. P. Davis Structure-Activity Relationships of a Series of [D-Ala2]Deltorphin I and II Analogues; in Vitro Blood-Brain Barrier Permeability and Stability J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 817 - 825. [Abstract] [Full Text]

				S. A. Thomas, T. J. Abbruscato, V. J. Hruby, and T. P. Davis The Entry of [D-Penicillamine2,5]Enkephalin into the Central Nervous System: Saturation Kinetics and Specificity J. Pharmacol. Exp. Ther., March 1, 1997; 280(3): 1235 - 1240. [Abstract] [Full Text]

				I. Tamai, Y. Sai, H. Kobayashi, M. Kamata, T. Wakamiya, and A. Tsuji Structure-Internalization Relationship for Adsorptive-Mediated Endocytosis of Basic Peptides at the Blood-Brain Barrier J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 410 - 415. [Abstract] [Full Text]